Compare Stocks → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ATRANASDAQ:AVRONASDAQ:MGTXNASDAQ:PRTONASDAQ:REPL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATRAAtara Biotherapeutics$0.69-1.4%$0.74$0.20▼$3.08$70.73M0.713.17 million shs1.20 million shsAVROAVROBIO$1.28+1.6%$1.30$0.57▼$1.70$57.42M1.24317,367 shs104,197 shsMGTXMeiraGTx$6.07-2.3%$6.25$3.49▼$8.35$398.79M1.3149,523 shs175,172 shsPRTOProteon Therapeutics$4.01+0.3%$19.37$0.22▼$3.94$88.94M0.61.11 million shs83,563 shsREPLReplimune Group$8.17-1.0%$8.10$5.89▼$24.81$506.45M1.221.19 million shs1.10 million shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATRAAtara Biotherapeutics-0.86%+3.74%-12.70%+35.34%-76.71%AVROAVROBIO+1.59%+2.40%-1.54%-5.88%+31.96%MGTXMeiraGTx-2.25%-6.04%-1.46%-13.53%+15.40%PRTOProteon Therapeutics+0.25%+2.82%-14.50%+109.95%+19.70%REPLReplimune Group-0.97%-0.37%-7.79%-3.08%-56.86%Central Banks Preparing for US Dollar Collapse? (Ad)China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATRAAtara Biotherapeutics3.9902 of 5 stars3.02.00.04.71.12.51.3AVROAVROBIO2.1109 of 5 stars3.03.00.00.03.31.70.6MGTXMeiraGTx4.6164 of 5 stars3.54.00.04.83.31.70.6PRTOProteon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AREPLReplimune Group4.4441 of 5 stars3.51.00.04.52.53.31.3Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATRAAtara Biotherapeutics2.00Hold$28.003,934.58% UpsideAVROAVROBIO2.00Hold$2.0056.25% UpsideMGTXMeiraGTx3.00Buy$25.67322.84% UpsidePRTOProteon TherapeuticsN/AN/AN/AN/AREPLReplimune Group3.00Buy$39.25380.42% UpsideCurrent Analyst RatingsLatest AVRO, ATRA, MGTX, PRTO, and REPL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/15/2024MGTXMeiraGTxRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATRAAtara Biotherapeutics$63.57M1.11N/AN/A$1.33 per share0.52AVROAVROBION/AN/A$0.29 per share4.40$2.13 per shareN/AMGTXMeiraGTx$14.02M27.80N/AN/A$2.17 per share2.80PRTOProteon TherapeuticsN/AN/AN/AN/A($0.06) per shareN/AREPLReplimune GroupN/AN/AN/AN/A$9.80 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATRAAtara Biotherapeutics-$228.30M-$2.78N/AN/AN/A-6,390.31%-783.31%-104.24%4/3/2024 (Estimated)AVROAVROBIO$12.16M-$0.10N/AN/AN/AN/A-74.86%-65.11%N/AMGTXMeiraGTx-$84.03M-$1.47N/A6.74N/A-599.47%-114.33%-42.56%5/9/2024 (Estimated)PRTOProteon Therapeutics-$20.73M-$1.15N/AN/AN/AN/AN/A-118.68%N/AREPLReplimune Group-$174.28M-$3.16N/AN/AN/AN/A-42.94%-35.80%5/16/2024 (Estimated)Latest AVRO, ATRA, MGTX, PRTO, and REPL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/8/2024Q3 2024REPLReplimune Group-$0.89-$0.77+$0.12-$0.77N/AN/A DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATRAAtara BiotherapeuticsN/AN/AN/AN/AN/AAVROAVROBION/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/APRTOProteon TherapeuticsN/AN/AN/AN/AN/AREPLReplimune GroupN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATRAAtara BiotherapeuticsN/A1.501.42AVROAVROBION/A15.7815.78MGTXMeiraGTx0.622.382.38PRTOProteon TherapeuticsN/A5.985.98REPLReplimune Group0.1612.4012.40OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATRAAtara Biotherapeutics70.90%AVROAVROBIO62.63%MGTXMeiraGTx67.48%PRTOProteon Therapeutics23.03%REPLReplimune Group92.53%Insider OwnershipCompanyInsider OwnershipATRAAtara Biotherapeutics4.50%AVROAVROBIO9.20%MGTXMeiraGTx9.70%PRTOProteon Therapeutics45.70%REPLReplimune Group20.60%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableATRAAtara Biotherapeutics334101.92 million97.34 millionOptionableAVROAVROBIO1344.86 million40.73 millionOptionableMGTXMeiraGTx41964.22 million57.99 millionOptionablePRTOProteon Therapeutics1722.18 millionN/ANot OptionableREPLReplimune Group28461.39 million48.74 millionOptionableAVRO, ATRA, MGTX, PRTO, and REPL HeadlinesSourceHeadlineReplimune appoints new CEO ahead of drug applicationuk.investing.com - March 29 at 12:50 AMPetri Dish: NIH sends BioNTech notice of default; Intellia ends Regeneron dealbizjournals.com - March 28 at 9:48 AMReplimune Names Sushil Patel as CEO in Broader Shakeupmarketwatch.com - March 26 at 12:12 PMReplimune Promotes Sushil Patel To Succeed Philip Astley-Sparke As CEOmarkets.businessinsider.com - March 26 at 12:12 PMReplimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitionsglobenewswire.com - March 26 at 7:30 AMReplimune Group (NASDAQ:REPL) Stock Price Up 5.3%marketbeat.com - March 21 at 4:24 PMREPL Apr 2024 10.000 callfinance.yahoo.com - March 16 at 12:31 PMREPL Mar 2024 10.000 putfinance.yahoo.com - March 15 at 4:28 PMHow Much Upside is Left in Replimune Group, Inc. (REPL)? Wall Street Analysts Think 50.17%zacks.com - March 11 at 10:56 AMWhat Makes Replimune Group, Inc. (REPL) a New Buy Stockzacks.com - March 8 at 1:01 PMReplimune to Present at the American Association for Cancer Research Annual Meeting 2024finance.yahoo.com - March 6 at 7:31 PMReplimune Group, Inc. (NASDAQ:REPL) Shares Sold by Redmile Group LLCmarketbeat.com - March 5 at 8:00 PMReplimune to Present at Three Upcoming Investor Conferencesfinance.yahoo.com - March 5 at 10:04 AMWall Street Analysts See a 70.57% Upside in Replimune Group, Inc. (REPL): Can the Stock Really Move This High?zacks.com - February 23 at 10:56 AMPositive Outlook for Replimune Group with Buy Rating and Increased Price Target Amidst Promising RP1 + Opdivo Therapy Trialsmarkets.businessinsider.com - February 15 at 6:48 PMAnalysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Replimune Group (REPL) and Phibro Animal Health (PAHC)markets.businessinsider.com - February 9 at 7:41 AMReplimune Group Is Worried About This – Should You Be Worried Too?msn.com - February 9 at 7:41 AMReplimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Updatefinance.yahoo.com - February 8 at 11:10 AMReplimune Group Inc (REPL) Reports Fiscal Q3 2024 Results and Extends Cash Runwayfinance.yahoo.com - February 8 at 11:10 AMReplimune Group Inc (REPL)investing.com - February 8 at 12:00 AMDisc Medicine Taps Ex-Replimune Exec for CFO, Promotes New Operations Chiefmarketwatch.com - February 7 at 8:58 AMSelling Buzz: Replimune Group Inc [REPL] Chief Medical Officer Xynos Konstantinos sells 7,313 shares of the companyknoxdaily.com - February 2 at 12:48 AMReplimune: The Fall Is Justified, As Virus Therapy Fails Again In Cancerseekingalpha.com - January 23 at 1:22 PMReplimune Group Inc (REPL) receives an Overweight rating from Piper Sandlerknoxdaily.com - January 4 at 12:14 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAtara BiotherapeuticsNASDAQ:ATRAAtara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.AVROBIONASDAQ:AVROAVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1, as well as to treat Gaucher disease type 3; AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease; AVR-RD-04, which is in phase 1/2 clinical trial for the treatment of cystinosis; and AVR-RD-05 that is in preclinical stage for the treatment of Hunter syndrome. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.MeiraGTxNASDAQ:MGTXMeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Proteon TherapeuticsNASDAQ:PRTOProteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.Replimune GroupNASDAQ:REPLReplimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.